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To determine if equine monocyte-derived dendritic cells (DC) were susceptible to equine infectious anemia virus (EIAV) infection, ex
vivo-generated DC were infected with virus in vitro. EIAV antigen was detected by immunofluorescence 3 days post-infection with
maximum antigen being detected on day 4, whereas there was no antigen detected in DC incubated with the same amount of heat-inactivated
EIAV. No cytolytic activity was observed after EIAVWSU5 infection of DC. These monocyte-derived DC were more effective than
macrophages and B cells in stimulating allogenic T lymphocytes. Both infected macrophages and DC stimulated similar levels of memory
CTL responses in mixtures of CD8+ and CD4+ cells as detected with 51Cr-release assays indicating that EIAV infection of DC did not alter
antigen presentation. However, EIAV-infected DC were more effective than infected macrophages when used to stimulate memory CTL in
isolated CD8+ cells. The maintenance of antigen processing and presenting function by EIAV-infected DC in vitro suggests that this function
is maintained during in vivo infection.
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It is clear that CTL are important for clearance of viral
infections (Byrne and Oldstone, 1984). With regard to
lentiviruses, experiments with simian immunodeficiency
virus infection of rhesus monkeys demonstrate the impor-
tance and necessity of CD8+ cells for control of this virus
during both the early and chronic stages of infection
(Schmitz et al., 1999). In addition, CTL activity is associated
with clearance of the initial viremia in both human
immunodeficiency virus-1 (HIV-1) (Borrow et al., 1994,
1997) and EIAV infections (McGuire et al., 1994). In
contrast, neutralizing antibody is not detected until after
the clearance of the initial viremia after either HIV-1 (Pilgrim
et al., 1997) or EIAV infection (Kono, 1968; O’Rourke et al.,
1988). Immunosuppression is common in HIV-1 and SIV-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1985). EIAV-infected horses experience a suppression of
immune responses during febrile episodes (Newman et al.,
1991). However, a key difference is the immunosuppression
observed in EIAV-infected horses is transient and infected
horses are usually able to control the initial and subsequent
viremias (Kono, 1968; Newman et al., 1991). Horses that are
infected with EIAV generally gain immune control of virus
within the first year of infection and become lifelong
inapparent carriers (Kono, 1968). These carriers have strong
antigen-specific CTL memory responses (Hammond et al.,
2000; McGuire et al., 2000; Zhang et al., 1998) whereas
HIV-1-infected individuals at later stages of disease have
severe defects in HIV-specific cellular immune responses
(Rowland-Jones, 2003).
Infection of DC by the maedi-visna virus (MVV), a
lentivirus of sheep that infects monocytes and macrophages,
but not lymphocytes, has been demonstrated in vivo and in
vitro (Ryan et al., 2000). HIV-1 infects human DC and there
are reports that HIV-1 infects DC more efficiently than05) 145 – 154
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production of high virus titers (Langhoff and Haseltine,
1992; Mallon et al., 1999). Also, in both symptomatic and
asymptomatic HIV-1 infection there are reduced numbers of
DC (Chehimi et al., 2002; Donaghy et al., 2001; Pacanow-
ski et al., 2001). Whether EIAV infects DC is not yet known,
however it infects monocytes and macrophages both in vitro
(Kobayashi and Kono, 1967) and in vivo (Maury et al.,
1998; McGuire et al., 1971; Oaks et al., 1998; Sellon et al.,
1992) and also infects endothelial cells (Oaks et al., 1999).
EIAV is not known to infect lymphocytes as occurs with the
lentiviruses that cause immunodeficiency (Klatzmann et al.,
1984; Letvin et al., 1985; Pedersen et al., 1987). Wild-type
EIAV has a cytopathic effect on cultured macrophages
which can be observed as early as 36 h post-infection
(Crawford et al., 1978; Kobayashi and Kono, 1967).
Equine DC can be isolated from PBMC by separating
the low-density DC from high-density lymphocytes
(Siedek et al., 1997). The DC were defined by their lack
of reaction in flow cytometry with monoclonal antibody
(mab) to surface markers that identify other cells in equine
PBMC. Equine DC have also been generated ex vivo from
monocytes using recombinant human granulocyte-macro-
phage colony stimulating factor (rhuGM-CSF) and recombi-
nant equine IL-4 (reqIL-4) (Hammond et al., 1999). Both
studies demonstrated a potent stimulatory capacity of equine
DC in the mixed leukocyte response (MLR). The latter study
demonstrated that addition of EIAV to monocyte-derived
equine DC induced proliferation of memory T lymphocytes.
However, EIAV infection of equine DC was not demon-
strated. Equine DC have also been used to stimulate memory
CTL to equine herpes virus-1 in PBMC from equine herpes
virus-1-infected horses (Soboll et al., 2003).
Because EIAV infects cells of the monocyte-macrophage
lineage, we hypothesized that EIAV infects equine DC and
that infection does not impede their antigen presenting
capability. The rationale for the latter is that EIAV-infected
horses are able to mount an immune response to control the
initial viremia, as are HIV-1 patients, but infected horses are
also able to control subsequent viral episodes. Furthermore,
EIAV-infected horses are able to respond to other antigens
and do not have opportunistic infections. We report here that
monocyte-derived DC from naive horses could be infected
with EIAV and that infected DC were able to stimulate
strong EIAV-specific memory CTL responses detected with
51Cr-release assays.Results
Surface phenotype of ex vivo generated equine DC
DC generated by culturing monocytes from PBMC for
3–4 days in the presence of rhuGM-CSF and reqIL-4 were
separated from lymphocytes using Nycoprep and are
referred to hereafter as DC. Analysis of these DC by flowcytometry demonstrated 70% of the cells were positive for
an equine myeloid marker DH59B (Fig. 1). There were 94%
of the ex vivo generated DC positive for MHC class I;
whereas 78% expressed MHC class II (Fig. 1). There were
approximately 5% contaminating B cells and less than 4%
contaminating CD3+ T cells (Fig. 1). Overall, these ex vivo
generated equine DC had a surface phenotype similar to that
previously described for equine DC generated by the same
procedures (Hammond et al., 1999).
Stimulation of mixed lymphocyte responses (MLR) with DC
DC were generated by culturing monocytes from PBMC
for 3–4 days in the presence of rhuGM-CSF and reqIL-4.
These cytokine-treated monocytes were separated from
lymphocytes using Nycoprep and are referred to hereafter
as DC. Equine monocyte-derived DC were compared with
isolated macrophages and B lymphocytes for their ability to
stimulate allogeneic T lymphocytes in an MLR. Represen-
tative data from one of four pairs of horses are presented in
Fig. 2. Even though the amount of stimulation as measured
by [3H]-thymidine incorporation varied with different pairs
of horses, equine DC always caused greater stimulation of
allogeneic T lymphocytes than either isolated macrophages
or B-lymphocytes. When fewer numbers of stimulators
were evaluated, DC remained superior in stimulating
allogeneic T lymphocytes (Fig. 2). Macrophages were
never very effective in inducing proliferation of allogeneic
T lymphocytes. Autologous PBMC did not cause signifi-
cant proliferation of T lymphocytes (data not shown).
EIAV infection of ex vivo generated DC
Isolated equine DC were evaluated for their susceptibility
to infection with EIAVWSU5. The isolated DC were infected
with EIAVWSU5 at an MOI of 5 and examined over 5 days.
FITC-conjugated polyclonal antibodies made from EIAV-
infected horse serum was used to evaluate infection and it
was first detected in the DC on day 3 and the brightest
fluorescent signal was observed on day 4 (Fig. 3). The
FITC-conjugated polyclonal antibody detects mainly the
Env glycoproteins and the Gag capsid protein (O’Rourke et
al., 1988). The percentage of DC infected with EIAV was
90%. Productive infection of DC was demonstrated by
exposing DC to heat-inactivated virus at the same MOI and
for the same amount of time as non-heat-inactivated virus.
No viral antigen was detected in the DC exposed to the
same amount of heat-inactivated virus. As compared to
macrophages, the ex vivo generated DC produced more
viral antigen as evidenced by larger and brighter areas of
intracytoplasmic fluorescence (data not shown). A similar
increase in viral antigen occurs in human dendritic cells
infected with HIV-1 (Langhoff and Haseltine, 1992).
The equine DC generated in this study were not killed by
EIAVWSU5 infection since the infected and uninfected cells
had similar viability over 5 days as determined by either
Fig. 1. Surface phenotype of ex vivo generated DC. Histograms of cell frequency ( y-axis) and log fluorescence intensity (x-axis) from flow cytometry analysis
of 3-day cultured DC reacted with various mab are presented: (A) isotype control mab, mab DH59B to a myeloid marker, mab H58A to MHC class I, mab
H42A to MHC class II and panel B; isotype control mab, mab B29 to B cells, and mab F6.6 to equine CD3. The bars represent the gates set using the isotype
control mab fluorescence as the negative control and the numbers under the bars are percentage of positive cells.
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Fig. 2. MLR stimulation with equine DC. A constant number of horse 112
responders (5  105) were incubated with increasing numbers of horse 174
irradiated stimulators. The stimulation index (SI) was calculated as the cpm
of stimulated cells divided by the cpm of unstimulated cells.
Table 1
Dendritic cell (DC) yield from EIAV-infected and uninfected horses
Horse number
and status
PBMCa
starting
number
DC yield
from PBMC
% DC
from
PBMC
H-174 uninfected 4.5  108 5.1  106 1.1
H-579 uninfected 3.0  108 3.0  106 1.0
A-2164 uninfected 4.5  108 2  107 4.4
A-2171 uninfected 6.3  108 1.8  107 2.8
Mean T SD 1.1  107 T 8.7  106 2.3 T 1.6
H-622 EIAV-infected 4  108 2.4  107 6.0
H-614 EIAV-infected 1  109 1.7  107 1.7
A-2150 EIAV-infected 1.2  109 8.5  106 0.7
A-2140 EIAV-infected 1  108 2.3  106 2.3
Mean T SD 1.3  107 T 9.5  106 2.6 T 2.3
a PBMC indicates peripheral blood mononuclear cells.
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formation occurring with infection by some lentiviruses is not
usually seen in EIAV infection of macrophages and was not
seen in EIAV-infected DC during the period of observation.
DC yield from uninfected and long-term EIAV-infected
horses
A comparison between four long-term EIAV-infected and
four uninfected horses was done to determine if infected
horses had reduced monocyte-derived dendritic cell num-
bers. Although there was a wide range in the percentage of
DC generated from PBMC, there was no significant
difference between the two groups (Table 1). The mean
percentage of DC generated from PBMC from the eight
horses was 2.5 T 1.85% SD (Table 1).Fig. 3. Demonstration of EIAV infection of equine dendritic cells using immunoflu
days and stained with an FITC-labeled polyclonal antibody to EIAV. (C) Uninfect
DC infected with EIAVWSU5 for 4 days then cytospun and stained with the sam
cytospun and stained with the same labeled antibody. (F) Uninfected non-adherenStimulation of MLR with EIAV-infected and uninfected DC
To study the capability of EIAV-infected DC to
stimulate allogeneic T lymphocytes, equine DC were
infected at an MOI of 5. DC from three different
uninfected horses, H-620, A-2190, and A-2192, were
infected with EIAVWSU5. Responder PBMC were from
uninfected horse A-2185. DC from all three horses
stimulated allogenic T lymphocytes (Fig. 4). Uninfected
and EIAV-infected DC from horse A-2190 stimulated
similar responses demonstrating that EIAV infection of
DC did not inhibit the activation of allogenic T lympho-
cytes (Fig. 4). Similar responses were seen with H-620
DC, although EIAV-infected DC from H-620 stimulated a
higher response than uninfected DC (Fig. 4). DC from A-
2192 were the most effective at stimulating allogenic T
lymphocytes whether they were uninfected or infected with
EIAV (Fig. 4). Autologous PBMC never caused significant
stimulation. Overall, EIAV infection of DC did not inhibitorescence. (A and B) Adherent dendritic cells infected with EIAVWSU5 for 4
ed adherent cells stained with the same labeled antibody. (D) Non-adheren
e labeled antibody. (E) A single non-adherent EIAVWSU5-infected DC was
t cells stained with the same labeled antibody.t
Fig. 5. Ex vivo generated equine DC stimulate a memory CTL response.
CD8+ and CD4+ cells from EIAV-infected horse A-2140 were stimulated
for 6 days with autologous DC, macrophages (Mac), or freshly isolated B
cells exposed to EIAVWSU5. As a control, CD8+ and CD4+ cells were
stimulated with EIAVWSU5 without addition of APC (None). After
stimulation, effectors were added to autologous EIAVWSU5-infected or
uninfected kidney target cells. The vertical bars indicate one SE.
Fig. 6. Enhanced stimulation of memory CTL in isolated CD8+ cells with
DC. DC and macrophages were infected with EIAVWSU5 and cultured for 7
days with isolated autologous CD8+ cells obtained from EIAV-infected
horse 2150. (˝) CD8+ cells and DC+ virus, ( ) CD8+ cells and
macrophages + virus. No significant specific lysis was observed with
CD8+ cells and virus only. The vertical bars indicate one SE. Asterisks
indicate a significant difference (>3 SE) between specific lysis with DC and
macrophages.
Fig. 4. Comparison of MLR stimulation with EIAV-infected and uninfected
DC. A constant number of horse A-2185 responders (5  105) were
incubated with increasing numbers of horse H-620, A-2190, or A-2192
stimulators for 5 days. Horse A-2185 did not respond to autologous PBMC
as stimulators (not shown). The vertical bars indicate one SE.
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infection of DC enhanced the stimulatory capacity of DC
from one horse.
Comparison of EIAV-infected DC and macrophages in
stimulation of memory CTL
In order to determine the capability of DC to stimulate a
memory CTL response, DC were compared with isolated
macrophages. DC and macrophages were cultured for 3
days and infected with EIAVWSU5 at an MOI of 5 and used
as APC. CD8+ and CD4+ effector cells were positively
selected from PBMC from an EIAV-infected horse in order
to remove APC. Either autologous DC or macrophages
were incubated with a mixture containing an equal number
of isolated CD8+ and CD4+ effector cells for 6 days.
Then, the effectors were tested for CTL activity using
EIAVWSU5-infected and uninfected autologous EK cells as
targets. These EK cells express MHC class I, but not MHC
class II (McGuire et al., 1997), and are restricted to CD8+
T lymphocyte lysis. As shown in Fig. 5, stimulation of an
in vitro memory response with the two different EIAV-
infected APC resulted in a significant increase in killing
above that caused by the mixture of CD8+ and CD4+
effectors without added APC. Culture of the CD8+ and
CD4+ cell mixture with virus alone and no added APC
resulted in 17% specific lysis (Fig. 5). This increase in
specific lysis over background was probably due to
residual APC stimulating the effector population. There
was no difference in stimulation by EIAV-infected DC
compared to EIAV-infected macrophages at any of the
effector-to-target cell ratios evaluated. No significant lysis
was observed using uninfected targets indicating that the
lysis was EIAV specific. It was concluded that exposure of
DC and macrophages to EIAV resulted in infection of
these cell types but did not affect their ability to stimulate
memory CTL activity as evaluated with 51Cr-release assays
(Fig. 5).DC were more effective than macrophages in stimulating
memory CTL in isolated CD8+ cells
Since no significant difference was observed between
DC and macrophages in stimulating memory CTL in a
mixture of isolated CD8+ and CD4+ cells, DC and
macrophages were compared for their ability to stimulate
memory CTL in isolated CD8+ cells. CD8+ cells were
positively selected from PBMC from an EIAV-infected
horse using magnetic beads and stimulated with different
numbers of either EIAV-infected autologous DC or macro-
phages. After 5–7 days stimulation, they were tested for
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targets. DC-stimulated autologous CD8+ cells caused
significant lysis of EIAV-infected targets as compared to
macrophage-stimulated CD8+ cells (Fig. 6). As all effector
cell to DC ratios tested, the percentage of specific lysis of
EIAV-infected targets was >3 SE above uninfected targets
which was considered statistically significant. Macrophage-
stimulated CD8+ cells caused a small amount of lysis of
infected targets, but the lysis was never significantly greater
than that of uninfected targets. Therefore, EIAV-infected DC
were more effective stimulators of isolated CD8+ CTL than
EIAV-infected macrophages.Discussion
This study demonstrated that ex vivo generated mono-
cyte-derived equine DC can be infected with EIAV. The
infection was shown by staining with a polyclonal FITC-
conjugated antibody derived from the serum of an EIAV-
infected horse. DC incubated with similar amounts of heat-
inactivated EIAV were not infected as they did not have
viral antigen detectable by immunofluorescence. Even
though 90% or more of the DC were infected, they
retained their antigen processing and presenting capabil-
ities as demonstrated by stimulation of allogenic MLR,
stimulation of EIAV-specific memory CTL in mixtures of
CD8+ and CD4+ cells, and stimulation of isolated
autologous CD8+ cells. In vitro infection of DC with
EIAVWSU5 was not cytolytic and furthermore, the yield of
monocyte-derived DC from EIAV-infected or uninfected
horses was similar. EIAVWSU5 was derived in horses from
a tissue culture-adapted strain (O’Rourke et al., 1988), and
it is possible that wild type strains could have different
effects on DC.
The allogenic MLR has routinely been used to evaluate
DC function because they are the most effective APC at
stimulating this reaction (Mellman and Steinman, 2001).
The mechanisms involved in MLR stimulation are not
known, but MHC class II molecules play a significant role
(Tourkova et al., 2001). Apparently, cell-to-cell contact is
not necessary as supernatants from DC are able to stimulate
allogenic T lymphocytes (Bedford et al., 1999). In this
study, equine DC were more effective than macrophages or
B lymphocytes in stimulating allogenic T lymphocytes. The
observation of equine DC being most effective at stimulat-
ing an MLR is similar to previous results with equine DC
and results from other species (Barratt-Boyes et al., 1998;
Fan et al., 1997; Hammond et al., 1999; Palucka and
Banchereau, 1999; Siedek et al., 1997).
Furthermore, equine DC infected with EIAV in vitro
stimulated allogenic T lymphocytes just as effectively as
uninfected DC. This is in contrast to enriched fractions of
HIV-1-infected monocyte-derived DC which were poor
stimulators of allogenic T cells (Kawamura et al., 2003).
However, depending on the MOI used to infect DC in vitrowith HIV-1, DC may or may not be able to stimulate an
MLR. (Blauvelt et al., 1997). HIV-1-infected individuals
experience decreases in DC as well as functional defects in
DC as disease progresses (Chehimi et al., 2002; Donaghy et
al., 2003; Pacanowski et al., 2001; Roberts et al., 1994). It
may be that the level of natural HIV-1 infection determines
the fate of DC in vivo (Barron et al., 2003; Donaghy et al.,
2003).
DC are known for their importance in stimulating
primary immune responses and there is evidence for a
critical role for DC in maintaining memory responses as
well (Ludewig et al., 1999; Sun and Bevan, 2003; van
Essen et al., 2000) including maintenance of protective
CTL-mediated immunity (Ludewig et al., 1999). In the
present study, DC and macrophages infected with
EIAVWSU5 were used as APC and both cell types stimulated
similar killing by autologous memory CTL in a mixture of
CD8+ and CD4+ cells. This result was unexpected as DC
are reported to express higher levels of co-stimulatory
molecules than other APC (Banchereau et al., 2000).
Similar stimulatory capacities by both DC and macrophages
may be explained by memory CTL having lower activation
requirements than naı¨ve T lymphocytes (Whitmire et al.,
2000). Nevertheless, equine DC stimulated a significant
memory CTL response in isolated autologous CD8+ cells,
whereas macrophages did not. Comparable results were
demonstrated in vitro using DC to prime naı¨ve CD8+ T
lymphocytes from humans (Zarling et al., 1999). That
EIAV-infected DC, but not macrophages, were able to
stimulate memory CTL in isolated CD8+ cells without
CD4+ cell help suggested important differences in antigen
processing and/or presenting pathways in DC as compared
to macrophages. Further, EIAV infection in vitro had no
detectable effect on DC antigen processing and presenta-
tion. Therefore, if EIAV infects DC in vivo, antigen
presentation functions may be spared allowing continuous
CTL stimulation.
The results presented herein are in contrast to HIV-1
infection of humans where known subsets of DC decrease in
parallel with diminishing memory CTL (Chehimi et al.,
2002; Donaghy et al., 2001; Pacanowski et al., 2001;
Rowland-Jones, 2003). The loss of CTL activity observed in
HIV-1-infected humans could be due in part to loss of DC
and to antigen-processing and presenting defects in the
remaining DC (Fan et al., 1997; Grassi et al., 1999;
Kawamura et al., 2003; Macatonia et al., 1989). While
DC can stimulate naı¨ve CD8+ T lymphocytes without
CD4+ T lymphocyte help, the subsequent memory
responses are inefficient (Sun and Bevan, 2003; Zarling
et al., 1999). Thus, the effect of the loss of DC and a loss
of function in the remaining DC on HIV-1-specific memory
CTL is exacerbated by the loss of CD4+ T helper
lymphocytes (Donaghy et al., 2001, 2003; Knight et al.,
1993a, 1993b; Macatonia et al., 1992; Sun and Bevan,
2003). Unlike CTL in the late stages of HIV-1 infection of
humans, EIAV-specific memory CTL responses can rou-
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(McGuire et al., 1997; Zhang et al., 1998).
In conclusion, this study demonstrated that EIAV can
infect ex vivo-derived equine DC from naı¨ve horses.
However, the number of DC that were generated from
PBMC was similar in uninfected and EIAV carrier horses.
EIAVWSU5 infection of DC in vitro did not kill the cells nor
inhibit their stimulatory capacity for allogenic T lympho-
cytes. Further, DC infection did not inhibit antigen
processing and presenting capabilities to memory CTL. In
particular, EIAV-infected DC were more effective than
infected macrophages at stimulating memory CTL in
isolated CD8+ cells supporting the elevated status of DC
in the hierarchy of professional APC that stimulate recall
responses. That EIAV can infect DC provides a strategy for
targeting these cells with non-infectious vaccines. More
specifically, non-infectious, EIAV-vectored vaccines could
be used to target DC resulting in the endogenous production
of EIAV antigen and effective CTL stimulation.Materials and methods
Horses and virus strains
Infected horses included two mixed breed ponies, H-
614 and H-622, infected with EIAVPV for 31 months
(Ridgely et al., 2003) and two Arabian horses, A-2140
and A-2150, infected with EIAVWSU5 for 40 and 41
months, respectively (Mealey et al., 2003). The derivation
of EIAVWSU5 (O’Rourke et al., 1988) and EIAVPV
(Rwambo et al., 1990) has also been described. Unin-
fected mixed breed pony H-620 and uninfected Arabian
horses A-2185, A-2190, A-2192, 112, and 174 were used
as uninfected PBMC sources for these experiments. All in
vitro experiments with virus were done with EIAVWSU5.
Generation of DC
DC were generated ex vivo using a described procedure
(Hammond et al., 1999). Briefly, PBMC were isolated from
settled blood cells by underlaying with FICOLL (ﬂ = 1.077)
and centrifuging. The 1–2  108 PBMC were plated onto
150 mm diameter tissue culture-treated dishes (Nunc,
Naperville, IL) in 15 ml of RPMI-C (RPMI 1640 supple-
mented with 10% heat-inactivated horse serum, 10 Ag/ml
gentamycin, 4 mM L-glutamine, and 50 AM h-mercapto-
ethanol). PBMC were incubated for 4 h at 37 -C with 5%
CO2 in a humid chamber, and then non-adherent cells were
removed by gently washing two times with PBS. The
remaining adherent cell population was incubated for 3 days
in RPMI-C supplemented with 1000 U/ml rhuGM-CSF
(Sigma, St. Louis, Mo.) and 500 U/ml reqIL-4. The units for
reqIL-4 were determined using PBMC in proliferation
assays (Rossio, 1997). The reqIL-4 was obtained from
transfected Chinese hamster ovary cells as described(Hammond et al., 1999; Vandergrifft et al., 1994). These
cells were provided by Dr. David Horohov, University of
Kentucky, Lexington, Kentucky.
After 3–4 days incubation, adherent and non-adherent
cells were harvested. The adherent cells were harvested by
incubation with 4 mM EDTA in RPMI-C with 10% heat-
inactivated horse serum for 1–2 h at 37 -C. Following this
procedure, the remaining adherent cells were removed with
a cell scraper. The non-adherent and adherent DC were
pooled and separated from lymphocytes by exploiting
differences in cell densities. Low density DC and high
density lymphocytes were separated using Nycoprep (ﬂ =
1.068) (Oslo, Norway). DC were collected at the interface of
RPMI and Nycoprep and maintained at 37 -C in RPMI-C
supplemented with 1000 U/ml rhuGM-CSF and 500 U/ml
reqIL-4 until needed. The phenotype of DC generated in this
manner was evaluated using a panel of mab and flow
cytometry. The mab panel included mab H58A to MHC
class I (VMRD, Inc., Pullman, WA), mab H42A to MHC
class II (VMRD, Inc.), mab DH59B to an equine myeloid
marker detected with (VMRD, Inc.), mab F6.6 to equine
CD3 (Serotec, Raleigh, NC), and mab B29 to equine B cells
(VMRD, Inc.). These monocyte-derived DC were used in
subsequent experiments including the MLR and in 51Cr
release assays.
EIAV infection of DC
DC were generated as described above using 1  106
PBMC per well and placed in 4-well chamber slides
(Lab-TekII, Nalge Nunc Int., Naperville, IL) and infected
at an MOI of 5 with EIAVWSU5. Infected cells were
cultured for 5 days and assayed for infection on days 3,
4, and 5. To discriminate between infection of DC and
viral antigen uptake by DC, EIAVWSU5 was incubated at
56 -C for 1 h in order to heat-inactivate the virus. DC
were exposed to heat-inactivated virus at an MOI of five
and cultured for 5 days and also assayed for infection on
days 3, 4, and 5. Following cell culture, the non-adherent
cells were removed and the remaining adherent cells were
gently washed with 500 Al of RPMI-C by adding the
medium to the side of the well, gently swirling and then
removing the medium by pipetting. A gentle wash was
necessary to prevent removing lightly adherent DC. The
slides were then air dried and fixed in 100% methanol.
The non-adherent fraction was cytospun onto glass slides
and fixed for staining. FITC-conjugated EIAV-specific
polyclonal antibody was used to detect infection
(Cheevers et al., 1978; Crawford et al., 1971). A Zeiss
microscope with a digital imager was used to photograph
the infected cells.
Viability determination
DC were infected with EIAVWSU5 at an MOI of 5 or
were uninfected as a control and plated in duplicate.
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were diluted in 0.25% trypan blue in PBS and cells were
counted in duplicate at 100 cells per field. Alternatively,
DC viability was determined using propidium iodide (PI)
exclusion. Ten microliters of a 50 Ag/ml PI stock solution
was added to DC samples suspended in 100 Al RPMI-C. A
flow cytometer was used to analyze the percentage of
stained cells.
Mixed lymphocyte response (MLR)
DC, macrophages, and B lymphocytes were tested for
their ability to stimulate allogenic T lymphocytes in an
MLR. Allogeneic responder cells were PBMC plated at 5 
105 cells per well in a round bottom 96-well plate.
Stimulator cells were irradiated, re-suspended to 2  106
cells/ml, then serially diluted 1:2 before adding to responder
cells in triplicate. DC were generated as described above
and used after 3–4 days in culture. Macrophages were
isolated by culturing PBMC overnight in plastic flasks and
removing non-adherent cells by washing with PBS. RPMI-
C was added to the adherent macrophages and they were
used on the third day of culture. B lymphocytes were
negatively selected using 4 Am diameter iron beads (Dynal
Biotech ASA, Oslo, Norway) coated with mab (CD2, mab
HB88A; CD4, mab HB61A; CD8, mab HT14A from
VMRD, Inc.) each at 1 Ag per 107 beads to remove T
lymphocytes and mab DH59B (VMRD, Inc.) to remove
equine neutrophils, macrophages, and most DC. Mixed
lymphocyte cultures were incubated for 5 days at 37 -C with
5% CO2 in a humid chamber.
3H-thymidine was added 18 h
before harvest. Stimulation index was calculated as the
mean cpm of triplicate test wells divided by mean cpm of
triplicate unstimulated responders. Alternatively, DC were
generated as described above then infected with EIAVWSU5
at an MOI of 5 and cultured for 24 h and then used in the
MLR.
51Chromium release assay
CTL were detected using 51Cr-release assays with a 17-h
incubation period as previously described (McGuire et al.,
1994). Autologous equine kidney (EK) cells established
from biopsies from horses before EIAV infection were used
as targets in 51Cr-release assays. EK cells were infected with
EIAVWSU5 at an MOI of 5 and incubated for 6 days before
use. Magnetic beads (Dynal Biotech ASA, Oslo, Norway)
were used to positively select CD4+ and CD8+ cells from
PBMC for use as effectors. Beads were coated with 1 Ag
monoclonal antibody per 107 beads using either anti-CD8
(HT14A, VMRD, Inc.) or anti-CD4 (HB61A, VMRD, Inc.).
The manufacturer’s protocol for using magnetic beads was
followed except for an extended washing. Briefly, following
positive selection, the bead/cell mixture was diluted to 10
times its original volume and pipetted gently to remove non-
adherent cells from bead-associated cells. Isolated CD4+and CD8+ cells were counted and mixed at a 1:1 ratio in
RPMI-C before adding APC for stimulation. Stimulating
APC were mixed with EIAVWSU5 at an MOI of 5 prior to
adding to the plated effectors at a 20:1 effector-to-stimulator
cell ratio. Cultures were incubated for 6 days at 37 -C with
5% CO2 in a humid chamber before being used as effectors
at a 20:1 effector–target cell ratio. The formula, % specific
lysis = [(E  S) / (M  S)]  100, was used, where E is the
mean of three test wells, S is the mean spontaneous release
from three target cell wells without effector cells, and M is
the mean maximal release from three target cell wells with
2% Triton X-100 in distilled water (Siliciano et al., 1985).Acknowledgments
We appreciate the technical assistance of Emma Karel,
Steve Leib, and Matt Littke. We also thank Wendy Brown
and Guy Palmer for advice and for critical review of this
manuscript. This research was supported in part by PHS,
NIH NIAID grant AI24291.References
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.,
Pulendran, B., Palucka, K., 2000. Immunobiology of dendritic cells.
Annu. Rev. Immunol. 18, 767–811.
Barratt-Boyes, S., Kao, H., Finn, O.J., 1998. Chimpanzee dendritic cells
derived in vitro from blood monocytes and pulsed with antigen elicit
specific immune responses in vivo. J. Immunother. 21, 142–148.
Barron, M.A., Blyveis, N., Palmer, B.E., MaWhinney, S., Wilson, C.C.,
2003. Influence of plasma viremia on defects in number and
immunophenotype of blood dendritic cell subsets in human
immunodeficiency virus 1-infected individuals. J. Infect. Dis. 187,
26–37.
Bedford, P., Garner, K., Knight, S.C., 1999. MHC class II molecules
transferred between allogeneic dendritic cells stimulate primary mixed
leukocyte reactions. Intern. Immunol. 11, 1739–1744.
Blauvelt, A., Asada, H., Saville, M.W., Klaus-Kovtun, V., Altman, A.J.,
Yarchoan, R., Katz, S.I., 1997. Productive infection of DC by HIV-1
and their ability to capture virus are mediated through separate
pathways. J. Clin. Invest. 100, 2043–2053.
Borrow, P., Lewicki, H., Hahn, B., Shaw, G., Oldstone, M.B.A., 1994.
Virus-specific CD8+ cytotoic T-lymphocyte activity associated with
control of viremia in primary human immunodeficiency virus type 1
infection. J. Virol. 68, 6103–6110.
Borrow, P., Lewicki, H., Wei, X., Horwitz, M.S., Peffer, N., Meyers, H.,
Nelson, J.A., Gairin, J.E., Hahn, B.H., Oldstone, M.B.A., Shaw, G.M.,
1997. Antiviral pressure exerted by HIV-1 specific cytotoxic T
lymphocytes (CTLs) during primary infection demonstrated by rapid
selection of CTL escape virus. Nat. Med. 3, 205–211.
Byrne, J.A., Oldstone, M.B.A., 1984. Biology of cloned cytotoxic T
lymphocytes specific for lymphocytic choriomeningitis virus: clearance
of virus in vivo. J. Virol. 51, 682–686.
Cheevers, W.P., Ackley, C.W., Crawford, T.B., 1978. Structural proteins of
equine infectious anemia virus. J. Virol. 28, 991–1001.
Chehimi, J., Campbell, D., Azzoni, L., Bacheeller, D., Papasavvas, E.,
Jeerandi, G., Mounzer, K., Kostman, J., Trinchieri, G., Montaner, L.,
2002. Persistent decreases in blood plasmacytoid dendritic cell
number and function despite effective highly active antiretroviral
therapy and increased blood myeloid dendritic cells in HIV-infected
individuals. J. Immunol. 168, 4796–4801.
J.A. Rivera, T.C. McGuire / Virology 335 (2005) 145–154 153Crawford, T.B., McGuire, T.C., Henson, J.B., 1971. Detection of equine
infectious anemia virus in vitro by immunofluorescence. Arch. Gesamte
Virusforsch. 34, 332–339.
Crawford, T.B., Cheevers, W.P., Klevjer-Anderson, P., McGuire, T.C.,
1978. Equine infectious anemia: virion characteristics, virus-cell
interaction and host responses. ‘‘Persistent viruses’’ ICN/UCLA
symposia on Molecular and Cell Biol vol. XI. Academic Press,
pp. 727–749.
Donaghy, H., Pozniak, A., Gazzard, B., Qazi, N., Gilmour, J., Gotch, F.,
Patterson, S., 2001. Loss of blood CD11c+ myeloid and CD11c
plasmacytoid dendritic cells in patients with HIV-1 infection correlates
with HIV-1 RNA virus load. Blood 98, 2574–2576.
Donaghy, H., Gazzard, B., Gotch, F., Patterson, S., 2003. Dysfunction
and infection of freshly isolated blood myeloid and plasmacytoid
dendritic cells in patients infected with HIV-1. Immunobiology 101,
4505–4511.
Fan, Z., Huang, X., Zheng, L., Wilson, C., Borowski, L., Liebmann, J.,
Gupts, P., Margolick, J., Rinaldo, C., 1997. Cultured blood dendritic
cells retain HIV-1 antigen-presenting capacity for memory CTL during
progressive HIV-1 infection. J. Immunol. 159, 4973–4982.
Grassi, F., Hosmalin, A., McIlroy, D., Calvez, V., Debre, P., Autran, B.,
1999. Depletion in blood CD11c-positive dendritic cells from HIV-
infected patients. AIDS 13, 759–766.
Hammond, S.A., Horohov, D., Montelaro, R.C., 1999. Functional
characterization of equine dendritic cells propagated ex vivo using
recombinant human GM-CSF and recombinant equine IL-4. Vet.
Immunol. Immunopathol. 71, 197–214.
Hammond, S.A., Li, F., McKeon, B.M., Cook, S., Issel, C.J., Montelaro,
R.C., 2000. Immune responses and viral replication in long-term
inapparent carrier ponies inoculated with equine infectious anemia
virus. J. Virol. 74, 5968–5981.
Kawamura, T., Gatanaga, H., Borris, D.L., Connors, M., Mitsuya, H.,
Blauvelt, A., 2003. Decreased stimulation of CD4+ T cell proliferation
and IL-2 production by highly enriched populations of HIV-infected
dendritic cells. J. Immunol. 170, 4260–4266.
Klatzmann, D., Barre-Sinoussi, F., Nugeyre, M.T., Dauguet, C., Vilmer,
E., Griscelli, C., Brun-Vezinet, F., Rouzioux, C., Gluckman, J.C.,
Chermann, J., 1984. Selective tropism of lymphadenopathy associ-
ated virus (LAV) for helper-inducer T lymphocytes. Science 225,
59–63.
Knight, S.C., Macatonia, S.E., Cruickshank, K., Rudge, P., Patterson, S.,
1993a. Dendritic cells in HIV-1 and HTLV-1 infection. Adv. Exp. Med.
Biol. 329, 545–549.
Knight, S.C., Macatonia, S.E., Patterson, S., 1993b. Infection of dendritic
cells with HIV-1 virus load regulates stimulation and suppression of T-
cell activity. Res. Virol. 144, 75–80.
Kobayashi, K., Kono, K., 1967. Propagation and titration of equine
infectious anemia virus in horse leukocyte culture. Natl. Inst. Anim.
Health Q. 7, 8–20.
Kono, Y., 1968. Viremia and immunological responses in horses infected
with equine infectious anemia virus. Natl. Inst. Anim. Health Q. 9,
1–9.
Langhoff, E., Haseltine, W.A., 1992. Infection of accessory dendritic cells
by human immunodeficiency virus type 1. J. Invest. Dermatol. 99,
89s–94s.
Letvin, N.L., Daniel, M.D., Sehgal, P.K., Desrosiers, R.C., Hunt, R.D.,
Waldron, L.M., MacKey, J.J., Schmidt, D.K., Chalifoux, L.V., King,
N.W., 1985. Induction of AIDS-like disease in macaque monkeys with
T-cell tropic retrovirus STLV-III. Science 230, 71–73.
Ludewig, B., Oehen, S., Barchiesi, F., Schwendener, R.A., Hengartner,
H., Zinkernagel, R.M., 1999. Protective antiviral cytotoxic T cell
memory is most efficiently maintained by restimulation via dendritic
cells. J. Immunol. 163, 1839–1844.
Macatonia, S.E., Patterson, S., Knight, S.C., 1989. Suppression of
immune responses by dendritic cells infected with HIV. Immunology
67, 285–289.
Macatonia, S.E., Gompels, M., Pinching, A.J., Patterson, S., Knight, S.C.,1992. Antigen-presentation by macrophages but not by dendritic cells
in human immunodeficiency virus (HIV) infection. Immunology 75,
576–581.
Mallon, D.FJ., Buck, A., Reece, C.J., Crowe, S.M., Cameron, P.U., 1999.
Monocyte-derived dendritic cells as a model for the study of HIV-1
infection: productive infection and phenotypic changes during culture in
human serum. Immunol. Cell Biol. 77, 442–450.
Maury, W., Oaks, J.L., Bradley, S., 1998. Equine endothelial cells support
productive infection of equine infectious anemia virus. J. Virol. 72,
9291–9297.
McGuire, T.C., Crawford, T.B., Henson, J.B., 1971. Immunofluorescent
localization of equine infectious anemia virus in tissue. Am. J. Pathol.
62, 283–292.
McGuire, T.C., Tumas, D.B., Byrne, K.M., Hines, M.T., Leib, S.R.,
Brassfield, A.L., O’Rourke, K.I., Perryman, L.E., 1994. Major
histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes
from horses with equine infectious anemia virus recognize Env and
Gag/PR proteins. J. Virol. 68, 1459–1467.
McGuire, T.C., Zhang, W., Hines, M.T., Henney, P.J., Byrnes, K.M.,
1997. Frequency of memory cytotoxic T lymphocytes to equine
infectious anemia virus proteins in blood from carrier horses. Virology
238, 85–93.
McGuire, T.C., Leib, S.R., Lonning, S.M., Zhang, W., Byrne, K.M.,
Mealey, R.H., 2000. Equine infectious anemia virus proteins with
epitopes most frequently recognized by cytotoxic T lymphocytes from
infected horses. J. Gen. Virol. 81, 2735–2739.
Mealey, R.H., Zhang, B., Leib, S.R., Littke, M.H., McGuire, T., 2003.
Epitope specificity is critical for high and moderate avidity cytotoxic
T lymphocytes associated with control of viral load and clinical
disease in horses with equine infectious anemia virus. Virology 313,
537–552.
Mellman, I., Steinman, R.M., 2001. Dendritic cells: specialized and
regulated antigen processing machines. Cell 106, 255–258.
Newman, M.J., Issel, C.J., Truax, R.E., Powell, M.D., Horohov, D.W.,
Montelaro, R.C., 1991. Transient suppression of equine immune
responses by equine infectious anemia virus (EIAV). Virology 184,
55–66.
Oaks, J.L., McGuire, T.C., Ulibarri, C., Crawford, T.B., 1998. Equine
infectious anemia virus is found in tissue macrophages during
subclinical infection. J. Virol. 72, 7263–7269.
Oaks, J.L., Ulibarri, C., Crawford, T.B., 1999. Endothelial cell infection in
vivo by equine infectious anaemia virus. J. Gen. Virol. 80, 2393–2397.
O’Rourke, K., Perryman, L.E., McGuire, T.C., 1988. Antiviral, anti-
glycoprotein and neutralizing antibodies in foals with equine infectious
anaemia virus. J. Gen. Virol. 69, 667–674.
Pacanowski, J., Kahi, S., Baillet, M., Lebon, P., Deveau, C., Goujard,
C., Meyer, L., Oksenhendler, E., Sinet, M., Hosmalin, A., 2001.
Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) den-
dritic cell numbers in primary HIV-1 infection. Immunobiology 98,
3016–3021.
Palucka, K., Banchereau, J., 1999. Dendritic cells: a link between innate
and adaptive immunity. J. Clin. Immunol. 19, 12–25.
Pedersen, N.C., Ho, E.W., Brown, M.L., Yamamoto, J.K., 1987. Isolation
of a T-lymphotropic virus from domestic cats with an immunodefi-
ciency-like syndrome. Science 235, 790–793.
Pilgrim, A.K., Pantaleo, G., Cohen, O.J., Fink, L.M., Zhou, J.Y., Zhou,
J.T., Bolognesi, D.P., Fauci, A.S., Montefiori, D.C., 1997. Neutralizing
antibody responses to human immunodeficiency virus type 1 in
primary infection and long-term-nonprogressive infection. J. Infect.
Dis. 176, 924–932.
Ridgely, S.L., Zhang, B., McGuire, T.C., 2003. Response of ELA-A1
horses immunized with lipopeptide containing an equine infectious
anemia virus ELA-A1-restricted CTL epitope to virus challenge.
Vaccine 21, 491–506.
Roberts, M., Gompels, M., Pinching, A.J., Knight, S.C., 1994. Dendritic
cells from HIV-1 infected individuals show reduced capacity to
stimulate autologous T-cell proliferation. Immunol. Lett. 43, 39–43.
J.A. Rivera, T.C. McGuire / Virology 335 (2005) 145–154154Rossio, J.L., 1997. Cytokines and immune cell products. In: Rose, N.R.,
de Macario, E.C., Folds, J.D., Lane, C., Nakamura, R.M. (Eds.),
Manual of Clinical Laboratory Immunology, ASM Press, Washington,
DC, pp. 348–356.
Rowland-Jones, S.L., 2003. AIDS pathogenesis: what have two decades of
HIV research taught us? Nat. Rev. 3, 343–348.
Ryan, S., Tiley, L., McConnell, I., Blacklaws, B., 2000. Infection of
dendritic cells by the maedi-visna lentivirus. J. Virol. 74, 10096–10103.
Rwambo, P.M., Issel, C.J., Hussain, K.A., Montelaro, R.C., 1990. In vitro
isolation of a neutralization escape mutant of equine infectious anemia
virus (EIAV). Arch. Virol. 111, 275–280.
Schmitz, J.E., Kuroda, M.J., Santra, S., Sasseville, V.G., Simon, M.A.,
Lifton, M.A., Racz, P., Tenner-racz, K., Dalesandro, M., Scallon, B.J.,
Ghrayeb, J., Forman, M.A., Montefioro, D.C., Rieber, E.P., Letvin, N.L.,
Reimann, K.A., 1999. Control of viremia in simian immunodeficiency
virus infection by CD8+ lymphocytes. Science 283, 857–860.
Sellon, D.C., Perry, S.T., Coggins, L., Fuller, F.J., 1992. Wild-type
equine infectious anemia virus replicates in vivo predominantly in
tissue macrophages, not in peripheral blood monocytes. J. Virol. 66,
5906–5913.
Siedek, E., Little, S., Mayall, S., Edington, N., Hamblin, A., 1997. Isolation
and characterisation of equine dendritic cells. Vet. Immunol. Immuno-
pathol. 60, 15–31.
Siliciano, R.F., Keegan, A.D., Dintzis, R.Z., Dintzis, H.M., Shin, H.S.,
1985. The interaction of nominal antigen with T cell antigen receptors:
I. Specific binding of multivalent nominal antigen to cytolytic T cell
clones. J. Immunol. 135, 906–914.Soboll, G., Whalley, J.M., Koen, M.T., Allen, G.P., Fraser, D.G.,
Macklin, M.D., Swain, W.F., Lunn, D.P., 2003. Identification of
equine herpesvirus-1 antigens recognized by cytotoxic T lymphocytes.
J. Gen. Virol. 84, 2625–2634.
Sun, J.C., Bevan, M.J., 2003. Defective CD8 T cell memory
following acute infection without CD4 T cell help. Science 300,
339–342.
Tourkova, I.L., Yurkovetsky, Z.R., Shurin, M.R., Shurin, G.V., 2001.
Mechanisms of dendritic cell-induced T cell poliferation in the primary
MLR assay. Immunol. Lett. 78, 75–82.
Vandergrifft, E.V., Swiderski, C.E., Horohov, D.W., 1994. Molecular
cloning and sequencing of equine interleukin 4. Vet. Immunol.
Immunopathol. 40, 379–384.
van Essen, D., Dullforce, P., Brocker, T., Gray, D., 2000. Cellular
interactions involved in Th cell memory. J. Immunol. 165,
3640–3646.
Whitmire, J.K., Murali-Krishna, K., Altman, J., Ahmed, R., 2000.
Antiviral CD4 and CD8 T-cell memory: differences in the size of the
response and activation requirements. Philos. Trans. R. Soc. London
355, 373–379.
Zarling, A.L., Johnson, J.G., Hoffman, R.W., Lee, D.R., 1999. Induction of
primary human CD8+ T lymphocyte responses in vitro using dendritic
cells. J. Immunol. 162, 5197–5204.
Zhang, W., Lonning, S.M., McGuire, T.C., 1998. Gag protein epitopes
recognized by ELA-A-restricted cytotoxic T lymphocytes from horses
with long-term equine infectious anemia virus infection. J. Virol. 72,
9612–9620.
